Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

被引：0
|
作者：
H. Xu
Q. Gong
F. D. Vogl
M. Reiner
J. H. Page
机构：
[1] Amgen Inc.,Center for Observational Research
[2] Amgen Inc.,Global Biostatistical Science
[3] Amgen Inc.,Hematology/Oncology
[4] Amgen Inc.,Global Biostatistical Science
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Bone pain; Chemotherapy; Pegfilgrastim; Risk factors; G-CSF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：723 / 730
页数：7
相关论文
共 50 条
  • [21] A Randomized, Single-Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim
    Guinigundo, Andrew S.
    Maxwell, Cathy L.
    Vanni, Linda
    Morrow, Phuong Khanh
    Reiner, Maureen
    Shih, Alex
    Klippel, Zandra
    Blanchard, Elizabeth
    PAIN MANAGEMENT NURSING, 2018, 19 (06) : 693 - 706
  • [22] Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice
    Lyman, Gary H.
    Richert-Boe, Kathryn
    Lamerato, Lois
    Kaur, Manpreet
    Shah, Neel
    Lawrence, Tatiana
    Sundaresan, Devi
    Silvia, Amanda
    Hanau, Ahuva
    Weycker, Derek
    BLOOD, 2019, 134
  • [23] Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy.
    Cosler, LE
    Eldar-Lissai, A
    Dale, DC
    Crawford, J
    Lyman, GH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 538S - 538S
  • [24] First and subsequent cycle pegfilgrastim results in low rates of neutropenic events in patients receiving myelosuppressive chemotherapy.
    Rader, ME
    Breyer, W
    Luedke, S
    Truscinski, D
    Ding, B
    Dansey, R
    Ozer, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S215 - S216
  • [25] In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer
    Danova, Marco
    Bencardino, Katia
    Manzoni, Mariangela
    Grasso, Donatella
    Mariucci, Sara
    Rovati, Bianca
    ANTICANCER RESEARCH, 2007, 27 (5A) : 3399 - 3402
  • [26] Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review
    Lyman, Gary H.
    Abella, Esteban
    Pettengell, Ruth
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 90 (03) : 190 - 199
  • [27] The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center.
    Leiva, Maya
    Pennisi, Angela
    Harnden, Kathleen Kiernan
    Rizzo, Patricia Conrad
    Mauro, Lauren Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Efficacy, Safety Profiles and Cost-effectiveness Analysis of Pegfilgrastim and Lenograstim in Patients with Non Metastatic Breast Cancer Receiving Adjuvant Myelosuppressive Chemotherapy
    Rossi, L.
    Lo Russo, G.
    Papa, A.
    Zoratto, F.
    Marzano, R.
    Basso, E.
    Giordani, E.
    Verrico, M.
    Pasciuti, G.
    Tomao, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S154 - S154
  • [29] The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies
    Whitworth, Jenny M.
    Matthews, Kellie S.
    Shipman, Kimberly A.
    Numnum, T. Michael
    Kendrick, James E.
    Kilgore, Larry C.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (03) : 601 - 604
  • [30] Risk factors for hospitalization in elderly cancer patients receiving chemotherapy
    Kleiner, J. M.
    Culakova, E.
    Dale, D. C.
    Crawford, J.
    Poniewierski, M. S.
    Wolff, D. A.
    Lyman, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345